James Labe, Director, Chief Executive Officer, on September 18, 2026, executed a purchase for 313,865 shares in Triplepoint Venture Growth BDC (TPVG) for $1,477,081. Following the Form 4 filing with the SEC, Labe has control over a total of 2,557,930 common shares of the company, with 245,326 shares held directly and 2,312,604 controlled indirectly.
SEC Filing:
Robert Schlossman, Chief Legal Officer, on September 21, 2026, sold 5,394 shares in Zscaler (ZS) for $1,078,800. Following the Form 4 filing with the SEC, Schlossman has control over a total of 61,591 common shares of the company, with 61,525 shares held directly and 66 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1713683/000171368326000182/xslF345X05/wk-form4_1790027535.xml
Stephen J Barnard, Director, Executive Chairman, on September 18, 2026, sold 35,562 shares in Mission Produce (AVO) for $446,177. Following the Form 4 filing with the SEC, Barnard has control over a total of 3,790,051 common shares of the company, with 287,459 shares held directly and 3,502,592 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1802974/000182580326000008/xslF345X05/wk-form4_1790026273.xml
Helen Louise Collins, Chief Medical Officer, on September 17, 2026, sold 5,000 shares in Enliven Therapeutics (ELVN) for $251,754. Following the Form 4 filing with the SEC, Collins has control over a total of 25,000 common shares of the company, with 25,000 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1672619/000170124726000013/xslF345X05/form4-09212026_090903.xml